[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sahar Mohammed Gad\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":4},"100536603",false,"NCT06266975","Chronic Kidney Disease Patient in Chronic Myloied Leukemia","Inclusion Criteria:1\\_ Chronic myloid leukemia patiants who diagonised by biopsy , 2\\_ CBC.\n\n\\-\n\nExclusion : 1\\_pts known to have CKD before diagnosed of CML. 2- known Diabetic pts 3-imaging suggestive CKD etiology rather than CML effect eg.PKD,renal stones,chronic pyelonephritis","ALL","18 Years","75 Years",{"count":18,"type":19},40,"ESTIMATED","OBSERVATIONAL","To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic myeloid leukemia .",[23],"Chronic Myeloid Leukemia in Remission","NOT_YET_RECRUITING","2024-02-16",{"date":27,"type":28},"2024-02-20","ACTUAL",{"date":30,"type":19},"2024-02",{"date":32,"type":19},"2026-11",{"name":34,"class":35},"Sahar Mohammed Gad","OTHER",""]